ReviewInternational journal of medical sciences2025
Advances in Tumor Antigen Vaccines: A New Frontier in Cancer Immunotherapy.
Review in International journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrative Spatial Transcriptomics and Immunoinformatics for Prognostic Multi-Epitope Vaccine Construct Prediction Against Synovial Sarcoma.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Artificial intelligence in peptide cancer vaccine design: from neoantigen discovery to immunogenicity prediction.Frontiers in genetics · 2026Review
- Immune interception in cancer: prioritizing vaccination in high-risk and premalignant settings.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the increasing prominence of cancer immunotherapy, therapeutic tumor vaccines have emerged as a promising strategy to enhance antitumor immunity by increasing tumor immunogenicity and activating the patient's immune system to inhibit tumor growth. However, their clinical efficacy is often limited due to insufficient immune cell infiltration, low antigen immunogenicity, and tumor immune escape mechanisms. To address these challenges, various innovative approaches have been explored, including the optimization of tumor antigen selection, the development of advanced vaccine platforms, and the combination of vaccines with other treatment strategies such as radiotherapy, chemotherapy, immune checkpoint inhibitors (ICIs), cytokine therapy, and adoptive T-cell transfer. This review provides a comprehensive summary of the mechanisms underlying tumor antigen vaccines, discusses recent advancements in vaccine design and combinatorial strategies, and assesses their potential to enhance therapeutic outcomes. We also highlight the ongoing challenges and future directions, underscoring the importance of interdisciplinary efforts to realize the full potential of tumor vaccines as a foundation of personalized cancer immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.